Lenalidomide Krka (Lenalidomide)

Lenalidomide binds to the cereblon protein within the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the complex’s target specificity, leading to the degradation of transcription factors Ikaros and Aiolos. The result is modulation of the immune response, inhibition of new blood‑vessel formation, and direct anti‑tumor activity.

The specific dose of Lenalidomide Krka is determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Healthcare providers set the appropriate regimen and adjust it as needed during treatment.

Lenalidomide is classified as pregnancy category X because it is known to cause fetal harm. It should not be used by pregnant women, and effective contraception is required for both men and women of reproductive potential. Breastfeeding is not recommended while taking lenalidomide.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both lenalidomide and thalidomide belong to the immunomodulatory drug class, but lenalidomide has a more favorable safety profile, especially regarding peripheral neuropathy. It also demonstrates stronger anti‑angiogenic and anti‑myeloma activity, making it the preferred option in many treatment protocols.

Lenalidomide Krka should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency.

Lenalidomide Krka is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablets are swallowed whole with a glass of water, and the dosing schedule is adjusted according to the treatment plan.

The most serious risks include severe neutropenia or leukopenia, which can lead to life‑threatening infections, and thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. Patients should be monitored closely for signs of infection or clotting, and appropriate preventive measures should be taken.

Lenalidomide Krka should not be used by individuals who are pregnant, planning to become pregnant, or who are not using reliable contraception. It is also contraindicated in patients with known hypersensitivity to lenalidomide or any of its excipients, and in those with uncontrolled thrombotic risk without appropriate prophylaxis.